Publications
Featured Publications
Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)
Journal for ImmunoTherapy in Cancer (JITC)
November 2023
Preclinical efficacy and immune activity of half-life extended IL-18 fusion proteins resistant to IL-18BP suppression
Society for Immunotherapy of Cancer (SITC)
November 2024
Tumor microenvironment pharmacodynamic effect of nemvaleukin less frequent intravenous dosing in multiple solid tumors: results from the phase 1/2 ARTISTRY-3 study
Society for Immunotherapy of Cancer (SITC)
November 2024
All Publications
A Novel, Individualized Xenograft Model of Cancer Immunotherapy and Tumor Growth Inhibition by ALKS 4230
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 2017
A Phase 1 Trial of ALKS 4230, an Engineered Cytokine Activator of NK and Effector T Cells, in Patients with Advanced Solid Tumors
American Society of Clinical Oncology (ASCO) Annual Meeting
June 2017
First-In-Human Dose Selection for ALKS 4230, an Investigational Immunotherapeutic Agent
American Association for Cancer Research (AACR) Annual Meeting
April 2017
Efficacy of ALKS 4230, a Novel Immunotherapeutic Agent, in Murine Syngeneic Tumor Models Alone and in Combination with Immune Checkpoint Inhibitors
American Association for Cancer Research (AACR) Annual Meeting
April 2017
Characterization of the Pharmacodynamic Immune Response to a Novel Immunotherapeutic Agent, ALKS 4230, in Mice and Non-Human Primates
American Association for Cancer Research (AACR) Annual Meeting
April 2017